Emerging evidence demonstrated that MSI and elevated TMB could heighten the anti-tumor activity of immunotherapy (Rizvi et al., 2015; Le et al., 2017; Mouw et al., 2017), and hence, we further investigated the ability of DMS to predict efficacy and prognosis of patients received anti-PD-1/PD-L1 antibody. This evidence concerns the gene CD274 and neoplasm.